Search Within

Steven M Horwitz

Formats
  1. Meeting Abstract (374)
  2. Journal Article (245)
  3. Review (13)
  4. Guidelines (11)
  5. Research Letter (9)
  6. Book Section (6)
  7. Editorial (4)
  8. Correspondence (3)
  9. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (666)
  2. Department of Medicine (666)
  3. Hematologic Malignancies, Division of (666)
  4. Lymphoma (666)
  5. Population Sciences Research Program (666)
  6. Survivorship Research (170)

More Groups

People
  1. Alison Moskowitz (233)
  2. Andrew Zelenetz (167)
  3. Paul Hamlin (138)
  4. Ariela Noy (137)
  5. David Straus (121)
  6. Maria Palomba (110)

More People

Years
  1. 2025 (14)
  2. 2024 (50)
  3. 2023 (41)
  4. 2022 (34)
  5. 2021 (53)
  6. 2020 (52)

More Years

Publications
  1. Blood (255)
  2. Journal of Clinical Oncology (64)
  3. Hematological Oncology (38)
  4. Leukemia and Lymphoma (19)
  5. Annals of Oncology (18)
  6. Blood Advances (18)

More Publications

Publishers
  1. American Society of Hematology (276)
  2. American Society of Clinical Oncology (65)
  3. Wiley Blackwell (55)
  4. Elsevier Inc. (33)
  5. Oxford University Press (25)
  6. Taylor & Francis Group (23)

More Publishers

Results (666)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes of patients with anaplastic large cell lymphoma, anaplastic lymphoma kinase-negative (ALCL, ALK-): Analysis of 203 patients prospectively registered in the International T-Cell Project
    Meeting Abstract

    Shustov, A.; Cabrera, M. E.; Bellei, M.; Ko, Y. H.; Manni, M.; Horwitz, S. M.; De Souza, C. A.; Radford, J. A.; Varela, S. B.; Prates, M. V.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • The role of upfront hematopoietic stem cell transplantation (HSCT) in peripheral T-cell lymphoma (PTCL) patients in complete remission (CR) with a special focus on nodal PTCL: Report from the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE), a prospective multicenter cohort study
    Meeting Abstract

    Park, S. I.; Horwitz, S. M.; Foss, F. M.; Pinter-Brown, L. C.; Carson, K. R.; Rosen, S. T.; Pro, B.; Hsi, E. D.; Federico, M.; Gisselbrecht, C.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: The largest multicenter retrospective analysis
    Meeting Abstract

    Mehta-Shah, N.; Teja, S.; Tao, Y.; Cashen, A. F.; Beaven, A.; Alpdogan, O.; Porcu, P.; Wiggin, M.; Song, K. W.; Alzahrani, M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Anti-CCR4 monoclonal antibody, mogamulizumab, demonstrates significant improvement in PFS compared to vorinostat in patients with previously treated cutaneous T-cell lymphoma (CTCL): Results from the phase III MAVORIC study
    Meeting Abstract

    Kim, Y. H.; Bagot, M.; Pinter-Brown, L.; Rook, A. H.; Porcu, P.; Horwitz, S. M.; Whittaker, S.; Tokura, Y.; Vermeer, M.; Zinzani, P. L.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • In vitro andpre-clinical in vivo evidence support MDMX/MDM2 as common vulnerabilities across TP53 -wild-type T-cell lymphomas that are targetable with the α-helical p53 stapled peptide ALRN-6924
    Meeting Abstract

    Koch, R.; Christie, A. L.; Yoshida, N.; Ng, S. Y.; Shigemori, K.; Morrow, S. N.; Van Scoyk, A.; Horwitz, S. M.; Jacobsen, E.; Santiago, S.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Genomic characteristics clinical phenotype and disease course of TP53 mutated diffuse large B cell lymphoma at diagnosis and relapse
    Meeting Abstract

    Joffe, E.; Batlevi, C. L.; Intlekofer, A. M.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Noy, A.; Straus, D. J.; Portlock, C. S.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Updated analyses of the international, open-label, randomized, phase 3 alcanza study: Longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL)
    Meeting Abstract

    Horwitz, S. M.; Scarisbrick, J. J.; Dummer, R.; Duvic, M.; Kim, Y. H.; Walewski, J.; Whittaker, S.; Quaglino, P.; Zinzani, P. L.; Wolter, P.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Interim results from a phase 1 study of ADCT-301 (camidanlumab tesirine) show promising activity of a novel pyrrolobenzodiazepine-based antibody drug conjugate in relapsed/refractory Hodgkin/non-Hodgkin lymphoma
    Meeting Abstract

    Horwitz, S. M.; Hamadani, M.; Fanale, M. A.; Feingold, J.; Spira, A. I.; Fields, P. A.; Menne, T.; Karnad, A.; Moskowitz, A. J.; Hildyard, C.; more...
    Blood (2017)

    Fulltext@MSK | Save